Importance Plasma neurofilament light (NfL) has been suggested as a noninvasive
biomarker to monitor neurodegeneration in Alzheimer disease (AD), but studies are lacking. …

Plasma biomarkers of amyloid, tau, and neurodegeneration (ATN) need to be characterized
in cognitively unimpaired (CU) elderly individuals. We therefore tested if plasma …

We developed models for individualized risk prediction of cognitive decline in mild cognitive
impairment (MCI) using plasma biomarkers of β-amyloid (Aβ), tau and neurodegeneration. …

Importance There is currently no consensus as to which biomarkers best predict longitudinal
tau accumulation at different clinical stages of Alzheimer disease (AD). Objective To …

Importance Neuronal and axonal destruction are hallmarks of neurodegenerative diseases,
but it is difficult to estimate the extent and progress of the damage in the disease process. …

Cost-effective strategies for identifying amyloid-β (Aβ) positivity in patients with cognitive
impairment are urgently needed with recent approvals of anti-Aβ immunotherapies for Alzheimer…

The Advanced Normalizations Tools ecosystem, known as ANTsX, consists of multiple open-source
software libraries which house top-performing algorithms used worldwide by …

Neurogranin (Ng) is a post-synaptic protein that previously has been shown to be a biomarker
for synaptic function when measured in cerebrospinal fluid (CSF). The CSF concentration …

Tau is an axonal microtubule-binding protein. Tau pathology in brain and increased tau
concentration in the cerebrospinal fluid (CSF) are hallmarks of Alzheimer’s disease (AD). Most of …

Background Recently, the anti-sense oligonucleotide drug nusinersen was approved for
spinal muscular atrophy (SMA) and our aim was to find a response marker for this treatment. …